BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 28393578)

  • 1. Kisspeptin as a promising oocyte maturation trigger for in vitro fertilisation in humans.
    Kasum M; Franulić D; Čehić E; Orešković S; Lila A; Ejubović E
    Gynecol Endocrinol; 2017 Aug; 33(8):583-587. PubMed ID: 28393578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The direct and indirect effects of kisspeptin-54 on granulosa lutein cell function.
    Owens LA; Abbara A; Lerner A; O'floinn S; Christopoulos G; Khanjani S; Islam R; Hardy K; Hanyaloglu AC; Lavery SA; Dhillo WS; Franks S
    Hum Reprod; 2018 Feb; 33(2):292-302. PubMed ID: 29206944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy.
    Abbara A; Jayasena CN; Christopoulos G; Narayanaswamy S; Izzi-Engbeaya C; Nijher GM; Comninos AN; Peters D; Buckley A; Ratnasabapathy R; Prague JK; Salim R; Lavery SA; Bloom SR; Szigeti M; Ashby DA; Trew GH; Dhillo WS
    J Clin Endocrinol Metab; 2015 Sep; 100(9):3322-31. PubMed ID: 26192876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ovarian hyperstimulation syndrome in the 21st century: the role of gonadotropin-releasing hormone agonist trigger and kisspeptin.
    Thomsen L; Humaidan P
    Curr Opin Obstet Gynecol; 2015 Jun; 27(3):210-4. PubMed ID: 25811256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial.
    Abbara A; Clarke S; Islam R; Prague JK; Comninos AN; Narayanaswamy S; Papadopoulou D; Roberts R; Izzi-Engbeaya C; Ratnasabapathy R; Nesbitt A; Vimalesvaran S; Salim R; Lavery SA; Bloom SR; Huson L; Trew GH; Dhillo WS
    Hum Reprod; 2017 Sep; 32(9):1915-1924. PubMed ID: 28854728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
    Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
    Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine Requirements for Oocyte Maturation Following hCG, GnRH Agonist, and Kisspeptin During IVF Treatment.
    Abbara A; Hunjan T; Ho VNA; Clarke SA; Comninos AN; Izzi-Engbeaya C; Ho TM; Trew GH; Hramyka A; Kelsey T; Salim R; Humaidan P; Vuong LN; Dhillo WS
    Front Endocrinol (Lausanne); 2020; 11():537205. PubMed ID: 33123084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of kisspeptin to trigger oocyte maturation during
    Sharma B; Koysombat K; Comninos AN; Dhillo WS; Abbara A
    Front Endocrinol (Lausanne); 2022; 13():972137. PubMed ID: 36147569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.
    Christopoulos G; Vlismas A; Carby A; Lavery S; Trew G
    Hum Fertil (Camb); 2016 Sep; 19(3):199-206. PubMed ID: 27662416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in IVF treatment.
    Abbara A; Islam R; Clarke SA; Jeffers L; Christopoulos G; Comninos AN; Salim R; Lavery SA; Vuong TNL; Humaidan P; Kelsey TW; Trew GH; Dhillo WS
    Clin Endocrinol (Oxf); 2018 Jun; 88(6):920-927. PubMed ID: 29446481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes.
    Zilberberg E; Haas J; Dar S; Kedem A; Machtinger R; Orvieto R
    Gynecol Endocrinol; 2015 Feb; 31(2):145-7. PubMed ID: 25385007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
    Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
    Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basic understanding of gonadotropin-releasing hormone-agonist triggering.
    Casper RF
    Fertil Steril; 2015 Apr; 103(4):867-9. PubMed ID: 25712575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of luteal phase defect and spontaneous pregnancy in IVF patients despite GnRH-agonist trigger and "freeze all policy" without luteal phase support: a report of four cases.
    Gurbuz AS; Deveer R; Ozcimen N; Ozcimen EE; Lawrenz B; Banker M; Garcia-Velasco JA; Fatemi HM
    Gynecol Endocrinol; 2016; 32(1):18-20. PubMed ID: 26487486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH; Wu FS; Lee RK; Li SH; Lin SY; Hwu YM
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadotropin-releasing hormone agonist (GnRHa) trigger - State of the art.
    Dosouto C; Haahr T; Humaidan P
    Reprod Biol; 2017 Mar; 17(1):1-8. PubMed ID: 28215488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.